Newsfeeds - Spark Newswire

1 minute read

House Committee Questions Eli Lilly, Sanofi, Novo Nordisk On ‘Unacceptably High’ Insulin Prices

Today, 10:20 PM

House Energy & Commerce Committee leaders sent three letters to execs at Eli Lilly And Co (NYSE:LLY), Sanofi SA (NASDAQ:SNY), and Novo Nordisk A/S (NYSE:NVO), raising…

LLY

1 minute read

Roche’s Arthritis Drug, Used As COVID-19 Treatment, Faces Supply Shortage

By Vandana Singh

Today, 10:20 PM

Genentech and Roche Holdings AG's (OTCQX: RHHBF) drug Actemra, or tocilizumab, was granted FDA emergency use authorization

RHHBF

2 minute read

Inside Sanofi’s $3.2B Translate Bio Buyout

By Vandana Singh

Today, 10:20 PM

Before the $3.2 billion acquisition of mRNA player Translate Bio Inc (NASDAQ:TBIO) earlier this month, Sanofi SA (NASDAQ:SNY) expressed interest in selling off around…

SNY

2 minute read

Unusual Options Activity Insight: Sanofi

By Benzinga Insights

Today, 10:20 PM

Sanofi (NASDAQ:SNY) shares experienced unusual options activity on Monday. The stock price moved up to $51.84 following the option alert.

SNY

7 minute read

The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight

By Shanthi Rexaline

Today, 10:20 PM

Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the week.

ABCL

1 minute read

FDA Approves Sanofi’s Enzyme Therapy For Late-Onset Pompe Disease

By Vandana Singh

Today, 10:20 PM

The FDA has approved Sanofi’s SA (NASDAQ:SNY) Nexviazyme (avalglucosidase alfa-ngpt) to treat patients one year of age and older with late-onset…

SNY

5 minute read

News

Sanofi Press Release Confirms Earlier Report FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease

By Michael Horton

Today, 10:20 PM

FDA approves Nexviazyme® (avalglucosidase alfa-ngpt), an important new treatment option for late-onset Pompe disease Approval is based on positive Phase 3 data demonstrating

SNY

1 minute read

News

FDA Approves New Treatment For Pompe Disease, Says Granted Approval Of Nexviazyme To Genzyme Corporation For Treatment Of Pompe Disease

By Michael Horton

Today, 10:20 PM

-Reuters

SNY

1 minute read

Sanofi – Regeneron’s Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung Cancer

By Vandana Singh

Today, 10:20 PM

The Phase 3 trial of Sanofi SA (NASDAQ:SNY) and Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Libtayo in combination with platinum-doublet chemotherapy was stopped early after…

REGN

7 minute read

The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO

By Shanthi Rexaline

Today, 10:20 PM

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)

ABSI